Betaine And Homocysteine — The Methyl Donor Nobody Mentions
Quick Read Your body has two separate systems for recycling homocysteine, an amino acid that builds up after you eat
We write a new article on supplements every day , all detailed, with citations.
Once a week we send an email containing a list of the last 7 days articles. Please sign up and also feel free to share the articles with friends and family who you think might benefit.
Simon Parrott – Vitacuity Ltd
Taking fish oil and absorbing it are two different things. The Omega-3 Index is a blood test that measures how much omega-3 has actually been incorporated into your red blood cells, giving a reliable three-month snapshot of your true omega-3 status. Two key fatty acids, EPA and DHA, embed themselves into cell membranes and help reduce inflammation and protect heart and brain health. Research suggests an index of 8% or above offers significant protection, but most people in the UK and US sit between 4% and 6%, putting them in the intermediate to high-risk zone.
The reason fish oil research has produced confusing results is that most studies give everyone the same dose regardless of where they start. Someone with an index of 3% will respond very differently from someone at 7%. Individual absorption varies greatly depending on body weight, genetics, and gut health, which is why actual blood levels matter far more than dietary questionnaires. Reaching and maintaining an index above 8% typically requires 1,000 to 2,000 mg or more of combined EPA and DHA daily, often higher than standard supplement doses provide.
Testing is now widely available through home finger-prick kits. If your index comes back below 6%, standard supplements are unlikely to get you into the target zone. Check supplement labels carefully, as EPA and DHA content varies enormously across products. Fish oil supplementation at these doses is extremely safe with minimal risk of harm.
Verdict: Most people taking fish oil are not absorbing enough to reach protective levels, but the Omega-3 Index test can tell you exactly where you stand and what dose you actually need.
You’ve been taking fish oil for years. Every morning, dutifully, a capsule or two with breakfast. You feel vaguely virtuous about it. But here’s the question almost nobody asks: is any of it actually getting into your cells? Because it turns out that taking fish oil and *absorbing* fish oil are two very different things, and for decades, scientists have been trying to understand why studies on omega-3 produce such wildly inconsistent results. The answer, it now seems, has been hiding in your red blood cells all along.
There is a blood test called the Omega-3 Index. It doesn’t measure what you eat or what’s floating through your bloodstream on a given Tuesday. It measures the actual EPA and DHA that has been incorporated into your red blood cell membranes, a far more stable, meaningful picture of your true omega-3 status. And what researchers have found when they started using this test consistently is striking. Most people in the UK, the US, and much of the Western world are sitting in a range that experts consider high risk. More on that in a moment.
To understand why this test matters, you need to understand what omega-3 fatty acids are actually doing in your body, and why measuring them in your blood plasma tells only part of the story.
EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) are the two long-chain omega-3s that do most of the heavy biological lifting. They work primarily by embedding themselves into cell membranes, the thin, flexible envelopes that surround every cell in your body, including heart muscle cells, brain neurons, and the red blood cells that carry oxygen around your system [12].
When EPA and DHA are present in sufficient quantities, they alter the physical characteristics of those membranes, making them more fluid and flexible. They influence the activity of membrane-bound proteins, interact with ion channels, and once released from membrane stores, they can be converted into a wide variety of anti-inflammatory compounds called eicosanoids, as well as specialised pro-resolving mediators, biological signals that help the body resolve inflammation rather than letting it smoulder indefinitely [12][13].
The Omega-3 Index, first formally described as a cardiovascular biomarker in the early 2000s, is simply the sum of EPA and DHA expressed as a percentage of all the fatty acids in red blood cell membranes [12]. Red blood cells are used because they live for roughly 90 to 120 days, which means the Omega-3 Index gives you a three-month average of your omega-3 status, similar to how HbA1c gives diabetics a three-month average of blood sugar. It’s stable, reproducible, and far more informative than a snapshot of what’s circulating in your plasma after last night’s salmon dinner [1][2].
The proposed risk zones, which have been refined and supported across multiple studies, are: – Below 4%, high risk – 4–8%, intermediate risk – 8–12%, the target zone, associated with optimal cardiovascular and brain protection [1][12]
Here’s the uncomfortable reality. In 2024, researchers updated a global map of Omega-3 Index levels using data from 342,864 subjects across 48 countries [4]. The findings were sobering.
Most countries fell into the “low” or “very low” categories. The UK and Ireland, despite improvements since a 2016 map, moved only from “very low” to “low”, meaning the average British person has an Omega-3 Index somewhere between 4% and 6%, sitting firmly in the intermediate-to-high risk zone rather than anywhere near the protective 8% threshold [4]. Countries with higher fish consumption, Finland, Iceland, Japan, fared considerably better, edging into the “desirable” range above 8%.
This matters because a low Omega-3 Index isn’t just a number on a lab report. Across 10 cohort studies pooling data on tens of thousands of people, researchers estimated that moving from an Omega-3 Index of around 4% to above 8% was associated with approximately a 30% reduction in risk of fatal coronary heart disease [15]. A 2026 review confirmed that levels below 4% are associated with very high risk of cardiovascular events and sudden death, while values above 8% indicate high cardiovascular protection [1].
Evidence grade: Promising to Strong. The cohort data is substantial and consistent. Randomised controlled trial data directly linking *raising* the Omega-3 Index to reduced cardiac events is still accumulating, but the epidemiological picture is compelling across multiple large datasets.
If you’ve ever read a headline saying “fish oil doesn’t work” and another one the following year saying “fish oil prevents heart attacks,” you’ve experienced the chaos that has plagued omega-3 research for decades. The Omega-3 Index may be the key to understanding why.
A 2023 review in a cardiology journal made a pointed observation: most of the large omega-3 trials that produced equivocal results treated EPA and DHA like a drug, giving everyone the same dose, regardless of where they started [7]. A person with an Omega-3 Index of 3% and a person with an index of 7% who both take the same supplement will respond completely differently. The person at 3% has enormous room to improve; the person at 7% is already partway there.
When researchers have looked at *blood levels* of EPA and DHA rather than just estimated dietary intake, the picture becomes much clearer. The Omega-3 Index correlates better with cardioprotective effects than dietary questionnaires [1], which is perhaps unsurprising, two people eating the same amount of fish can have dramatically different levels of absorption and incorporation into cell membranes, depending on their gut health, body composition, and genetics [3][7].
A 2025 study found that the Omega-3 Index actually *improves upon* the widely used Pooled Cohort Equation, the standard clinical tool for predicting 10-year cardiovascular risk, in predicting atherosclerotic cardiovascular disease [5]. That’s a significant claim: a supplement biomarker outperforming an established clinical risk calculator.
Evidence grade: Promising. The data supporting the Omega-3 Index as a superior biomarker over dietary questionnaires is consistent and compelling. Direct head-to-head comparison with clinical prediction tools is more recent and needs further replication.
This is where things get practically important. Reaching an Omega-3 Index of 8% or above requires more omega-3 than most people realise, and more than most standard supplement doses deliver.
A cross-sectional study of 3,458 adults (predominantly US-based) who self-tested their Omega-3 Index found a mean index of just 5.99% [6]. Among those following the American Heart Association’s recommendation of two fish meals per week but not supplementing, only 10% achieved an Omega-3 Index above 8%. Even in the highest intake group, eating three or more fish servings per week *and* taking a supplement, only 44% reached the target [6].
A separate study of 985 participants found that among those consuming at least two fatty fish servings per week, only those also taking an average of approximately 1,100 mg per day of supplemental EPA and DHA had a median Omega-3 Index above 8% [8]. The researchers also noted that the amount of EPA and DHA in supplements varied enormously, across more than 400 different products, EPA and DHA content ranged from just 50 mg to 3,570 mg per serving [8]. That’s a 70-fold difference. A generic “fish oil capsule” could contain almost nothing.
A randomised controlled trial in patients with peripheral arterial disease (n=80) provided particularly clean data: participants given 4.4 g of fish oil per day (providing 2.6 g EPA and 1.8 g DHA) for one month saw their Omega-3 Index rise from an average of 5.1% to 9.0%, comfortably into the target zone [14]. The placebo group showed no change.
Evidence grade: Strong for the relationship between dose and Omega-3 Index. Promising for optimal dose needed for general populations.
One finding that often goes unreported is that people vary considerably in how well they respond to the same fish oil dose. The OMEGA-PAD I trial found that factors associated with a better response to supplementation included a lower body mass index [14]. This makes biological sense: EPA and DHA are fat-soluble, and a larger body mass means more tissue for these fatty acids to distribute into before reaching the red blood cells, potentially diluting the measurable effect.
This individual variability is precisely why dietary questionnaires and rough intake estimates are such poor proxies for actual omega-3 status [3][9]. A study validating a dietary questionnaire against actual blood Omega-3 Index measurements found only moderate correlation (r=0.67) between reported intake and measured blood levels, meaning dietary recall gets the direction right much of the time, but can’t reliably tell you *where* someone actually sits on the risk spectrum [9].
The fish oil’s form also matters. A 2023 lipidomics study using randomised controlled trials found that DHA was significantly more effective at raising the Omega-3 Index than EPA alone, a DHA intervention raised the index by an average of 4.90%, compared to 2.99% for an EPA-only intervention [11]. Both matter, but their mechanisms and membrane distribution differ, which is why the type of omega-3 you take is not irrelevant.
Evidence grade: Promising. Individual response variation and the differential effects of EPA versus DHA on the Omega-3 Index are supported by controlled trial data, though sample sizes in some studies are modest.
The Omega-3 Index was conceived as a cardiovascular biomarker, but its use has expanded considerably. As of a 2025 review, 456 papers have cited the Omega-3 Index since its introduction 20 years ago, with 58 appearing in just the 18 months prior to publication [2]. The metric is now being used across research into brain health, neurological conditions, pregnancy outcomes, and eye health, all areas where EPA and DHA in cell membranes appear to play important biological roles [2][3].
The link to inflammation resolution is particularly compelling. In the OMEGA-PAD I trial, a doubling of the Omega-3 Index correlated with a 2.3-fold increase in a key pro-resolving inflammation mediator (18-HEPE), a 3.6-fold increase in another (4-HDoHE), and significant increases in multiple other downstream anti-inflammatory compounds [13]. This provides a biological mechanism, not just a statistical correlation, for why higher Omega-3 Index values are associated with better health outcomes across multiple conditions.
Evidence grade: Promising for brain and broader health applications. Strong for cardiovascular. Early stage for several newer applications.
The Omega-3 Index is an impressive and increasingly well-validated biomarker, but intellectual honesty requires acknowledging its limitations.
The causal question is not fully settled. Most of the evidence linking a higher Omega-3 Index to better health outcomes comes from cohort studies, which show association, not causation. While randomised controlled trials have demonstrated that supplementation raises the Omega-3 Index, fewer large RCTs have directly tested whether *raising* the index reduces clinical events in general populations [1][7].
EPA and DHA may not be interchangeable. Research increasingly suggests these two fatty acids behave differently in membranes and produce different downstream effects [10][11]. The Omega-3 Index captures them together, which may occasionally obscure important distinctions between them.
Standardisation of the test matters. Not all labs measure the Omega-3 Index the same way. Different methods, plasma, serum, whole blood, red blood cell membranes, produce different numbers, and comparing results across labs requires conversion equations that add uncertainty [3][4]. If you test today and retest six months later using a different lab’s methodology, the numbers may not be directly comparable.
The optimal target range may vary by condition. The 8–12% target range is primarily derived from cardiovascular research. Whether the same range is optimal for brain health, inflammation resolution, or pregnancy is less well established [2][3].
Body weight and BMI affect response. People with higher BMI may need substantially higher doses to achieve the same Omega-3 Index as leaner individuals, which means population-level supplement dose recommendations are necessarily imprecise for any given person [14].
Here is what a sensible, well-informed person should actually do with this information.
First, recognise that “I take fish oil” is not the same as “I have adequate omega-3 levels.” The research is unambiguous on this: most people in the UK are not anywhere near the protective range of 8%, even those taking standard fish oil capsules and eating fish twice a week [4][6]. The Omega-3 Index test is the only reliable way to know where you actually stand.
The good news is that Omega-3 Index testing is increasingly accessible. Home finger-prick blood spot tests are commercially available and can be done without a GP referral [3]. If you’ve never tested, it’s worth doing once to establish your baseline, particularly if you’re in the 40–65 age group where cardiovascular risk starts to climb meaningfully.
On dosing: if your Omega-3 Index comes back below 6%, the evidence strongly suggests that standard supplement doses (500–1,000 mg of combined EPA and DHA) are likely insufficient to move you into the target range. The trial data suggests that reaching and maintaining an index above 8% typically requires combined EPA and DHA intake in the range of 1,000–2,000 mg or more per day, and that combining supplementation with regular oily fish consumption gives you the best odds of getting there [6][8]. Check the label of your fish oil supplement carefully, the total “fish oil” figure on many products is not the same as the EPA and DHA content, which is what actually counts.
On the supplement itself: omega-3/fish oil supplementation at doses in this range is extremely safe. EPA and DHA are not stored in toxic amounts in the way some fat-soluble vitamins can be. The risk of genuine harm from supplementing is minimal; the risk of sitting in the low or very-low Omega-3 Index range for years is, based on the evidence, considerably more substantial [1][15]. If getting tested isn’t immediately practical, supplementing with a quality, high-dose EPA and DHA product (aim for 1,000–2,000 mg combined EPA+DHA daily) is a reasonable and low-risk default, and testing when you can to confirm you’re in the target zone is the next step.
Finally, check the quality and EPA/DHA content of what you’re taking. The research found over 400 different supplement products with EPA+DHA content ranging from 50 mg to 3,570 mg per serving [8]. That generic supermarket fish oil may be doing almost nothing measurable. Choose a product that clearly states its EPA and DHA content, not just its total fish oil content.
The Omega-3 Index doesn’t make fish oil more complicated. It makes it *honest*, and for something as important as long-term heart and brain health, honest information is exactly what you want.
*Vitacuity analysts reviewed over 1.77 million research papers to identify the most relevant and rigorous evidence on this topic. The 15 papers referenced here represent the current state of the science on the Omega-3 Index as a clinical and personal health tool.*
[1] Omega-3 Index: an emerging biomarker in cardiovascular prevention. (2026). DOI: 10.20960/nh.06965 | https://pubmed.ncbi.nlm.nih.gov/42377354/
[2] Recent studies confirm the utility of the omega-3 index. (2025). DOI: 10.1097/MCO.0000000000001078 | https://pubmed.ncbi.nlm.nih.gov/39514368/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11809719/
[3] ω-3 Polyunsaturated Fatty Acid Status Testing in Humans: A Narrative Review of Commercially Available Options. (2024). https://pubmed.ncbi.nlm.nih.gov/38522783/
[4] Omega-3 world map: 2024 update. (2024). https://pubmed.ncbi.nlm.nih.gov/38879135/
[5] Omega-3 index improves upon the pooled cohort equation in predicting risk for CVD. (2025). https://pubmed.ncbi.nlm.nih.gov/40074603/
[6] Association of reported fish intake and supplementation status with the omega-3 index. (2019). DOI: 10.1016/j.plefa.2019.01.002 | https://pubmed.ncbi.nlm.nih.gov/30773210/
[7] Omega-3 fatty acids in heart disease, why accurately measured levels matter. (2023). DOI: 10.1007/s12471-023-01759-2 | https://pubmed.ncbi.nlm.nih.gov/36795219/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10602979/
[8] Cross-sectional study of the combined associations of dietary and supplemental eicosapentaenoic acid + docosahexaenoic acid on Omega-3 Index. (2019). DOI: 10.1016/j.nutres.2019.09.001 | https://pubmed.ncbi.nlm.nih.gov/31757628/
[9] Validation of a Dietary Questionnaire to Screen Omega-3 Fatty Acids Levels in Healthy Adults. (2019). DOI: 10.3390/nu11071470 | https://pubmed.ncbi.nlm.nih.gov/31261632/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6682879/
[10] Ω-3 index as a prognosis tool in cardiovascular disease. (2017). DOI: 10.1097/MCO.0000000000000404 | https://pubmed.ncbi.nlm.nih.gov/28768293/
[11] Lipidomic studies reveal two specific circulating phosphatidylcholines as surrogate biomarkers of the omega-3 index. (2023). DOI: 10.1016/j.jlr.2023.100445 | https://pubmed.ncbi.nlm.nih.gov/37730162/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10622695/
[12] The omega-3 index as a risk factor for coronary heart disease. (2008). https://pubmed.ncbi.nlm.nih.gov/18541601/
[13] Relationship between the omega-3 index and specialized pro-resolving lipid mediators in patients with peripheral arterial disease taking fish oil supplements. (2017). DOI: 10.1016/j.jacl.2017.06.011 | https://pubmed.ncbi.nlm.nih.gov/28778393/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5612881/
[14] Predictors of change in omega-3 index with fish oil supplementation in peripheral artery disease. (2017). DOI: 10.1016/j.jss.2016.11.011 | https://pubmed.ncbi.nlm.nih.gov/28457318/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5412597/
[15] The Omega-3 Index and relative risk for coronary heart disease mortality: Estimation from 10 cohort studies. (2017). DOI: 10.1016/j.atherosclerosis.2017.05.007 | https://pubmed.ncbi.nlm.nih.gov/28511049/
This article is for informational purposes only and does not constitute medical advice. Food supplements should not be used as a substitute for a varied and balanced diet and healthy lifestyle. If you are pregnant, breastfeeding, taking medication or have a medical condition, consult your doctor before taking any supplement. These statements have not been evaluated by the Food and Drug Administration (FDA) or the Medicines and Healthcare products Regulatory Agency (MHRA). This product is not intended to diagnose, treat, cure, or prevent any disease.
Quick Read Your body has two separate systems for recycling homocysteine, an amino acid that builds up after you eat
Quick Read B vitamins become increasingly important for brain health after 40 because your body absorbs them less efficiently with
The nutrients that matter, the forms that work, and the claims to ignore.
